Anaplastic Lymphoma Kinase Inhibitor in Treatment of Inflammatory Myofibroblastic Tumor of the Tongue in Infancy.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 05 2021
01 05 2021
Historique:
received:
11
03
2020
accepted:
18
06
2020
pubmed:
10
8
2020
medline:
12
5
2021
entrez:
10
8
2020
Statut:
ppublish
Résumé
Inflammatory myofibroblastic tumors (IMTs) are rare in neonates. IMTs of the tongue are also very rare in infancy, with only 1 case reported in this age group. The mainstay of therapy has traditionally been surgery, which can be devastating to surrounding structures and negatively impact prognosis. Approximately 50% of IMTs harbor a translocation involving the anaplastic lymphoma kinase gene. We describe a case of IMT of the tongue in a neonate treated with debulking and an anaplastic lymphoma kinase inhibitor. The patient achieved complete response and remains disease-free 1.5 year following completion of therapy.
Identifiants
pubmed: 32769570
pii: 00043426-202105000-00023
doi: 10.1097/MPH.0000000000001907
doi:
Substances chimiques
Protein Kinase Inhibitors
0
ALK protein, human
EC 2.7.10.1
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e521-e524Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Mossé YP, Voss SD, Lim MS, et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children’s Oncology Group Study. J Clin Oncol. 2017;35:3215–3221.
Owusu-Brackett N, Johnson R, Schindel DT, et al. A novel ALK rearrangement in an inflammatory myofibroblastic tumor in a neonate. Cancer Genet. 2013;206:353–356.
Syed AU, Al Mutairi MB, Al Muhaya M, et al. Inflammatory myofibroblastic tumor of heart in a 4-month-old infant. Asian Cardiovasc Thorac Ann. 2018;26:47–49.
De Winkel N, Becker K, Vogt M. Echogenic mass in the right atrium after surgical ventricular septal defect closure: thrombus or tumour? Cardiol Young. 2010;20:86–88.
Tay SY, Balakrishnan A. Laryngeal inflammatory myofibroblastic tumor (IMT): a case report and review of the literature. J Med Case Rep. 2016;10:180.
Klein AM, Schoem SR, Altman A, et al. Inflammatory myofibroblastic tumor in the neonate: a case report. Otolaryngol Head Neck Surg. 2003;128:145–147.
Dalton BGA, Thomas PG, Sharp NE, et al. Inflammatory myofibroblastic tumors in children. J Pediatr Surg. 2016;51:541–544.
Ide F, Shimoyama T, Horie N. Sclerosing inflammatory myofibroblastic tumour of the tongue: an immunohistochemical and ultrastructural study. Oral Oncol. 2000;36:300–304.
Pankaj C, Uma C. How to manage oral inflammatory myofibroblastic tumor (inflammatory pseudotumor)? Oral Dis. 2001;7:315–316.
Gleizal A, Ranchere-Vince C, Beziat JL. Inflammatory myofibroblastic tumour of the tongue: a case report. Br J Oral Maxillofac Surg. 2007;45:423–424.
Lourenço SV, Boggio P, Simonsen Nico MM. Inflammatory myofibroblastic tumor of the tongue: report of an unusual case in a teenage patient. Dermatol Online J. 2012;18:6.
YucelEkici N, Bayindir T, Kizilay A, et al. Inflammatory myofibroblastic tumor: a rare tumor in the tongue. Case Rep Otolaryngol. 2013;2013:787824.
Caporalini C, Moscardi S, Tamburini A, et al. Inflammatory myofibroblastic tumor of the tongue. Report of a pediatric case and review of the literature. Fetal Pediatr Pathol. 2018;37:117–125.
Coffin CM, Fletcher JA Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. Inflammatory myofibroblastic tumour. World Health Organization Classification of Tumours WHO Classification of Soft Tissue and Bone, 4th ed. Lyon, France: IARC Press; 2013:83–84.
Devaney KO, LaFeir DJ, Triantafyllou A, et al. Inflammatory myofibroblastic tumors of the head and neck: evaluation of clinicopathologic and prognostic features. Eur Arch Otorhinolaryngol. 2012;269:2461–2465.
Lovly CM, Gupta A, Lipson D, et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov. 2014;4:889–895.
Hallberg B, Palmer RH. The role of the ALK receptor in cancer biology. Ann Oncol. 2016;27(suppl 3):iii4–iii15.
Coffin CM, Patel A, Perkins S, et al. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol. 2001;14:569–576.
Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–2177.
Mossé YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14:472–480.
Kiratli H, Uzun S, Varan A, et al. Management of anaplastic lymphoma kinase positive orbito-conjunctival inflammatory myofibroblastic tumor with crizotinib. J AAPOS. 2016;20:260–263.
Gaudichon J, Jeanne-Pasquier C, Deparis M, et al. Complete and repeated response of a metastatic ALK-rearranged inflammatory myofibroblastic tumor to crizotinib in a teenage girl. J Pediatr Hematol Oncol. 2016;38:308–311.
Theilen T-M, Soerensen J, Bochennek K, et al. Crizotinib in ALK+ inflammatory myofibroblastic tumors—current experience and future perspectives. Pediatr Blood Cancer. 2018; 4:65.
Alan O, Kuzhan O, Koca S, et al. How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature. J Oncol Pharm Pract. 2020;26:1011–1018.